Vol. 23/No. 11 | OncologyLive

Toolbox Overflows With First-Line Combination Regimens for Advanced RCC

June 14, 2022

Mehmet A. Bilen, MD, and a panel of renal cell carcinoma experts discuss the preferred treatment options for patients with intermediate-risk or high-risk advanced renal cell carcinoma and the clinical features that may influence their decisions.

BRUIN CLL-321 Aims to Expand BTK Inhibitor Options in CLL/SLL

June 08, 2022

The BRUIN CLL-321 trial is evaluating pirtobrutinib monotherapy compared with investigator’s choice of idelalisib plus rituximab or bendamustine plus rituximab among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have previously received covalent BTK inhibitor treatment.

NCCN Guidelines Affirm New Options for Resectable NSCLC

June 01, 2022

Cover Story

New systemic regimens are being integrated into the treatment paradigm for resectable non–small cell lung cancer in the neoadjuvant and adjuvant settings, expanding options for patients with earlier-stage disease who face a challenging prognosis.

Peer-Reviewed Data Present an Essential But Problematic Component of Oncology Research

May 31, 2022

There are serious concerns about textbook descriptions of peer review, specifically within the realm of clinical research, which pose a threat to both the objectivity of the field of investigative medicine and, perhaps most importantly, to the public’s support of clinical science.